Literature DB >> 11130566

Colorectal cancer screening by fecal occult blood testing: results of a population-based experience.

G Grazzini1, G Castiglione, A Isu, P Mantellini, T Rubeca, C Sani, P Turco, M Zappa.   

Abstract

AIMS AND
BACKGROUND: The study evaluated the results of an experimental screening protocol for colorectal cancer by fecal occult blood testing in a municipality of the Province of Florence.
METHODS: A total of 15,235 subjects aged 50-70 years were invited to perform a 1-day immunochemical fecal occult blood testing without any dietary restrictions. All eligible subjects were sent a personal invitation letter, followed by a postal reminder to non-responders. Subjects with a negative stool test were advised to repeat screening after 2 years. Subjects with a positive screening test were invited to undergo full colonoscopy or a combination of left colonoscopy and a double contrast barium enema.
RESULTS: A total of 6,418 subjects performed the screening test, with an overall compliance of 42.1%. A total of 268 compliers had positive test results. The positivity rate was 4.2%. Detection rate for cancer and for adenomas was 5.1% and 11.6%, respectively. The positive predictive value was 14.3% for cancer and 32.5% for adenoma. A higher compliance was recorded in subjects born in the province of Florence or living in the centre of the town, in married subjects, and in women. The best results in compliance were associated with the direct distribution of fecal occult blood testing kits by general practitioners to their outpatients.
CONCLUSIONS: The study provides useful information about the efficiency and feasibility of a screening program for colorectal cancer using fecal occult blood testing. Compliance results confirm the importance of GP involvement in oncological screening.

Entities:  

Mesh:

Year:  2000        PMID: 11130566     DOI: 10.1177/030089160008600503

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  7 in total

1.  Randomized controlled trial of the impact of intensive patient education on compliance with fecal occult blood testing.

Authors:  Charlene L Stokamer; Craig T Tenner; Jhuma Chaudhuri; Eva Vazquez; Edmund J Bini
Journal:  J Gen Intern Med       Date:  2005-03       Impact factor: 5.128

2.  Telephone reminder call in addition to mailing notification improved the acceptance rate of colonoscopy in patients with a positive fecal immunochemical test.

Authors:  Jae Myung Cha; Joung Il Lee; Kwang Ro Joo; Hyun Phil Shin; Jae Jun Park
Journal:  Dig Dis Sci       Date:  2011-06-18       Impact factor: 3.199

3.  The compliance rate for the second diagnostic evaluation after a positive fecal occult blood test: A systematic review and meta-analysis.

Authors:  Rachel Gingold-Belfer; Haim Leibovitzh; Doron Boltin; Nidal Issa; Tsachi Tsadok Perets; Ram Dickman; Yaron Niv
Journal:  United European Gastroenterol J       Date:  2019-02-06       Impact factor: 4.623

Review 4.  Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests: A Systematic Review.

Authors:  Kevin Selby; Christine Baumgartner; Theodore R Levin; Chyke A Doubeni; Ann G Zauber; Joanne Schottinger; Christopher D Jensen; Jeffrey K Lee; Douglas A Corley
Journal:  Ann Intern Med       Date:  2017-10-10       Impact factor: 25.391

5.  Can colorectal cancer mass-screening organization be evidence-based? Lessons from failures: the experimental and pilot phases of the Lazio program.

Authors:  Antonio Federici; Alessandra Barca; Diego Baiocchi; Francesco Quadrino; Sabrina Valle; Piero Borgia; Gabriella Guasticchi; Paolo Giorgi Rossi
Journal:  BMC Public Health       Date:  2008-09-19       Impact factor: 3.295

6.  Improving fecal occult blood testing compliance using a mailed educational reminder.

Authors:  Jeffrey K Lee; Veronica Reis; Shanglei Liu; Lorraine Conn; Erik J Groessl; Theodore G Ganiats; Samuel B Ho
Journal:  J Gen Intern Med       Date:  2009-09-23       Impact factor: 5.128

7.  Using physician-linked mailed invitations in an organised colorectal cancer screening programme: effectiveness and factors associated with response.

Authors:  Jill Tinmouth; Nancy N Baxter; Lawrence F Paszat; Linda Rabeneck; Rinku Sutradhar; Lingsong Yun
Journal:  BMJ Open       Date:  2014-03-12       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.